Hyperfine Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue reached a record $6.0M, up 73% YoY, with 56.7% gross margin and quarterly net cash burn of $5.6M. FY2026 revenue and burn guidance were reaffirmed, while the gross-margin floor was raised.
-
Revenue grew 45% year-over-year to $3.9 million in Q2 2026, with strong Model 2 adoption across hospitals, offices, and international markets. Gross margin exceeded 50% for the fourth consecutive quarter, and full-year guidance was reiterated, supported by a strengthened balance sheet and multiple growth catalysts.
-
Strong Q1 growth and robust financial outlook are driven by innovative portable MRI technology, regulatory clearances, and diversified revenue streams. Clinical data supports near-parity with conventional MRI, while future plans target expanded indications and broader market reach.
-
The meeting confirmed a quorum, elected five directors, and ratified the auditor appointment. No shareholder questions were raised, and all proposals passed with requisite votes. Forward-looking statements were noted as subject to risks in SEC filings.
-
Q1 2026 revenue rose 83% year-over-year to $3.9 million, with gross margin exceeding 50% and strong adoption across hospitals, neurology offices, and international markets. Guidance for 2026 is reiterated, projecting $20–$22 million in revenue and continued margin expansion.
Fiscal Year 2025
-
Q4 2025 revenue surged 128% year-over-year, driven by strong adoption of the next-gen Swoop system and Optive AI software, with robust growth in hospitals, neurology offices, and international markets. 2026 guidance projects 55% revenue growth and continued margin expansion.
-
A first-mover in portable brain MRI, the company leverages AI-driven innovation and a strong patent portfolio to expand across hospital, office, and international markets. Recent FDA clearance and commercial launches drive growth, with Q3 revenue up 27%.
-
Q3 2025 saw 27% sequential revenue growth, record gross margin, and reduced cash burn, driven by next-gen product launches and strong demand across hospital, office, and international markets. Guidance for Q4 and full-year 2025 was raised, with a strengthened capital position and cash runway into H2 2027.
-
A portable, AI-powered brain MRI platform is driving rapid adoption across hospitals and neurology offices, with a U.S. market opportunity exceeding $6 billion and strong early sales momentum. The latest FDA-cleared system offers near-conventional image quality and supports significant revenue growth.
-
Q2 2025 revenue rose 26% sequentially to $2.7M, with gross margin up to 49% and cash burn down 19%. FDA-cleared next-gen products and Optiv AI software drove strong adoption across hospitals, offices, and international markets, supporting a robust H2 2025 outlook.
-
A new FDA-cleared portable brain MRI system powered by Optiv AI is launching, offering improved image quality and broad care site applicability. With strong financials, a large addressable market, and international expansion plans, the company is poised for significant growth.
-
Q1 2025 revenue reached $2.1M with improved gross margin, but grant funding cuts impacted hospital sales. Diversification into office and international markets, new product launches, and cost controls are expected to drive growth and margin expansion in H2 2025.
Fiscal Year 2024
-
2024 saw 17% revenue growth, gross margin expansion, and reduced cash burn, with strategic moves into office, hospital, and international markets. 2025 guidance calls for 20%-30% revenue growth, higher margins, and a major second-half acceleration driven by new product launches.
-
Q3 2024 saw 56% revenue growth, record gross margins, and strong U.S. and international placements. AI-driven software advances and clinical data support expansion into new care settings, with 2024 guidance reaffirming ~30% growth and a cash runway into early 2026.
-
A proprietary, portable brain MRI platform is expanding access to diagnostic imaging across critical care, pediatrics, stroke, and Alzheimer's, with strong clinical evidence, global partnerships, and robust financial growth. Key studies and international expansion are set to accelerate growth in 2025.
-
Record Q2 revenue and gross margin were driven by strong U.S. and international sales, FDA-cleared AI software, and clinical progress in Alzheimer's and stroke. Raised 2024 revenue guidance and expects significant business acceleration in 2025, with new market and international expansion.
-
A portable, AI-powered brain MRI platform is expanding access to neurological imaging, targeting critical care, outpatient, and global low-resource settings. With strong financial growth, regulatory clearances, and a focus on Alzheimer's, the company is positioned for broad market impact.